



<b>Form PTO-1449 Modified</b>		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Jeffrey V. Ravetch</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
*	<del>AA</del>	<del>Ausubel, F.M., et al. (Eds.), Current Protocols in Molecular Biology, John Wiley &amp; Sons, Inc., 1994</del>	
M/B	AB	Baselga, J., et al., "Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts," <i>Cancer Res.</i> , July 1, 1998, 58, 2825-2831	
	AC	Bird, R.E., et al., "Single-chain antigen-binding proteins," <i>Science</i> , October 21, 1988, 242, 423-426	
	AD	Boder, E.T., et al., "Yeast surface display for screening combinatorial polypeptide libraries," <i>Nat. Biotechnol.</i> , June 1997, 15, 553-557	
	AE	Bolland, S., et al., "SHIP modulates immune receptor responses by regulating membrane association of Btk," <i>Immunity</i> , April 1998, 8, 509-516	
	AF	Brooks, D.G., et al., "Structure and expression of human IgG FcRII(CD32) functional heterogeneity is encoded by the alternatively spliced products of multiple genes," <i>J. Exp. Med.</i> , October 1989, 170, 1369-1385	
	AG	Buchwald, H., et al., "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis," <i>Surgery</i> , October 1980, 88(4), 507-516	
	AH	Burton, D.R., "Immunoglobulin G: functional sites," <i>Mol. Immunol.</i> , 1985, 22(3), 161-206	
	AI	Capel, P.J.A., et al., "Heterogeneity of human IgG Fc receptors," <i>Immunomethods</i> , 1994, 4, 25-34	
M/B	AJ	Carter, P., et al., "Humanization of an anti-p185 <sup>HER2</sup> antibody for human cancer therapy," <i>Proc. Natl. Acad. Sci. USA</i> , May 1992, 89, 4285-4289	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 10/01/02	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.




<b>Form PTO-1449 Modified</b>		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Jeffrey V. Ravetch</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<i>MB</i>	<b>AK</b>	Clackson, T., et al., "Making antibody fragments using phage display libraries," <i>Nature</i> , August 15, <b>1991</b> , 352, 624-628	
	<b>AL</b>	Cochet, O., et al., "Intracellular expression of an antibody fragment-neutralizing p21 Ras promotes tumor regression," <i>Cancer Res.</i> , March 15, <b>1998</b> , 58, 1170-1176	
	<b>AM</b>	Cox, A.L., et al., "Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines," <i>Science</i> , April 29, <b>1994</b> , 264, 716-719	
	<b>AN</b>	Curiel, D.T., et al., "High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes," <i>Hum. Gene Ther.</i> , <b>1992</b> , 3, 147-154	
	<b>AO</b>	Curiel, D.T., "Targeted tumor cytotoxicity mediated by intracellular single-chain anti-oncogene antibodies," Gene Therapy Program, <i>Advances in Pharmacology</i> , <b>1997</b> , 40, 51-84	
	<b>AP</b>	Daëron, M., "Fc receptor biology," <i>Annu. Rev. Immunol.</i> , <b>1997</b> , 15, 203-234	
	<b>AQ</b>	Damen, "The 145-kDa protein induced to associate with She by multiple cytokines is an inositol tetrakisphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1996</b> , 93, 1681693	
	<b>AR</b>	de Haas, M., et al., "Fcγ receptors of phagocytes," <i>J. Lab. Clin. Med.</i> , <b>1995</b> , 126, 330-341	
	<b>AS</b>	Deisenhofer, J., "Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from <i>Staphylococcus aureus</i> at 2.9- and 2.8-Å resolution," <i>Am. Chem. Soc.</i> , April 28, <b>1981</b> , 20(9), 2361-2370	
	<b>AT</b>	During, M.J., et al., "Controlled release of dopamine from a polymeric brain implant: in vivo characterization," <i>Ann. Neurol.</i> , <b>1989</b> , 25, 351-356	
<i>MB</i>	<b>AU</b>	Ellman, J., et al., "Biosynthetic method for introducing unnatural amino acids site-specifically into proteins," <i>Meth. In Enzym.</i> , <b>1991</b> , 202, 301-336	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
		<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<i>MB</i>	<b>AV</b>	Felgner, P.L., et al., "Cationic liposome-mediated transfection," <i>Nature</i> , January 26, 1989, 337, 387-388	
<i>MB</i>	<b>AW</b>	Felgner, P.L., et al., "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure," <i>Proc. Natl. Acad. Sci. USA</i> , November 1987, 84, 7413-7417	
*	<del><b>AX</b></del>	<del>Freshney, R.I. (Ed.), <i>Immobilized Cells and Enzymes</i>, IRL Press, 1986</del>	
	<b>AY</b>	Funakoshi, S., et al., "Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas," <i>J. Immunother.</i> , 1996, 19(2), 93-101	
*	<del><b>AZ</b></del>	<del>Gait, M.J. (Ed.), <i>Oligonucleotide Synthesis</i>, 1984</del>	
*	<del><b>BA</b></del>	<del>Glover, D.N. (Ed.), "DNA Cloning: A Practical Approach," Vols. I and II, 1985</del>	
<i>MB</i>	<b>BB</b>	Goodson, J.M., in <i>Medical Applications of Controlled Release</i> , 1984, Vol. 2, 115-138	
*	<del><b>BC</b></del>	<del>Hames, B.D., et al. (Eds.), <i>Nucleic Acid Hybridization</i>, 1985</del>	
<i>MB</i>	<b>BD</b>	Han, D.C., et al., "Therapy with antisense TGF- $\beta$ 1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice," <i>Am. J. Physiol. Renal Physiol.</i> , 2000, 278, F628-F634	
<i>MB</i>	<b>BE</b>	Hanna, A.K., et al., "Adenoviral-mediated expression of antisense RNA to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts," <i>J. Vasc. Surg.</i> , 2000, 31, 770-780	
<b>EXAMINER</b> <i>[Signature]</i>		<b>DATE CONSIDERED</b> <i>10/01/02</i>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.




<b>Form PTO-1449 M</b> <b>dated</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
		Applicant <b>Jeffrey V. Ravetch</b>	
		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<i>M/B</i>	<b>BF</b>	Howard, M.A., et al., "Intracerebral drug delivery in rats with lesion-induced memory deficits," <i>J. Neurosurg.</i> , <b>1989</b> , 71, 105-112	
	<b>BG</b>	Huse, W.D., et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda," <i>Science</i> , December 8, <b>1989</b> , 246, 1275-1281	
	<b>BH</b>	Huston, J.S., et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , August <b>1988</b> , 85, 5879-5883	
	<b>BI</b>	Jerome, K.R., et al., "Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognized an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells," <i>Cancer Res.</i> , June 1, <b>1991</b> , 51, 2908-2916	
<i>M/B</i>	<b>BJ</b>	Jones, P.T., et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> , May 29, <b>1986</b> , 321, 522-525	
*	<b>BK</b>	<del>Kabat, et al., "Sequences of Proteins of Immunological Interest, 5<sup>th</sup> Ed.," Public Health Service, National Institutes of Health, Bethesda, MD, <b>1991</b></del>	
<i>M/B</i>	<b>BL</b>	Kaplitt, M.G., et al., "Expression of a functional foreign gene in adult mammalian brain following <i>in vivo</i> transfer via a herpes simplex virus type 1 defective viral vector," <i>Mol. &amp; Cell. Neurosci.</i> , <b>1991</b> , 2, 320-330	
	<b>BM</b>	Kavanaugh, W.M., et al., "Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2," <i>Curr. Biol.</i> , <b>1996</b> , 6(4), 438-445	
	<b>BN</b>	Köhler, G., et al., <i>Nature</i> , August 7, <b>1975</b> , 256, 495-497	
<i>M/B</i>	<b>BO</b>	Kopreski, M.S., et al., "Growth inhibition of breast cancer cell lines by combinations of anti-P185 <sup>HER2</sup> monoclonal antibody and cytokines," <i>Anticancer Res.</i> , <b>1996</b> , 16, 433-436	
<b>EXAMINER</b> <i>[Signature]</i>		<b>DATE CONSIDERED</b> <i>10/01/02</i>	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
		<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
MB	BP	Langer, R., "New methods of drug delivery," <i>Science</i> , September 28, 1990, 249, 1527-1533	
*	BQ	<del>Langer, et al. (Eds.), "Medical Applications of Controlled Release," CRC Press, Boca Raton, Florida, 1974</del>	
MB	BR	Langer, R., et al., "Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: a review," <i>JMS-Rev. Macromol. Chem. Phys.</i> , 1983, C23(1), 61-126	
	BS	LaSalle, G.L., et al., "An adenovirus vector for gene transfer into neurons and glia in the brain," <i>Science</i> , February 12, 1993, 259, 988-990	
	BT	Lebkowski, J.S., et al., "Adeno-associated virus: a victor system for efficient introduction and integration of DNA into a variety of mammalian cell types," <i>Mol. and Cell Biol.</i> , 1988, 8(10), 3988-3996	
	BU	Leget, G.A., et al., "Use of rituximab, the new FDA-approved antibody," <i>Curr. Opin. In Oncol.</i> , 1998, 10, 548-551	
	BV	Leung, D.W., et al., "A method for random mutagenesis of a defined DNA segment using a modified polymerase chain reaction," <i>Technique, J. Methods in Cell &amp; Mol. Bio.</i> , August 1989, 1(1), 11-15	
	BW	Levy, R.J., et al., "Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate," <i>Science</i> , April 12, 1985, 228, 190-192	
	BX	Lewis, G.D., et al., "Differential responses of human tumor cell lines to anti-p185 <sup>HER2</sup> monoclonal antibodies," <i>Cancer Immunol. Immunother.</i> , 1993, 37, 255-263	
	BY	Lopez-Berestein, G., "Treatment of systemic fungal infections with liposomal-amphotericin B," in <i>Liposomal in the Therapy of Infectious Diseases and Cancer</i> , 1989, 317-327	
MB	BZ	Liu, J., et al., "Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE," <i>Biochem.</i> , 1995, 34, 10474-10482	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 10/01/02	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
		Applicant <b>Jeffrey V. Ravetch</b>	
		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<i>MB</i>	CA	Mack, A., et al., "The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5'butyrylcholinesterase-DNA study," <i>Prog. Neurobiol.</i> , 2000, 60, 607-628	
	CB	Machy, P., et al., "Gene transfer from targeted liposomes to specific lymphoid cells by eletroporation," <i>Proc. Natl. Acad. Sci. USA</i> , November 1988, 85, 8027-8031	
	CC	Marasco, W.A., et al., "Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy," <i>Hum. Gene Ther.</i> , July 20, 1998, 9, 1627-1642	
	CD	Marks, J.D., et al., "By-passing immunization human antibodies from V-gene libraries displayed on phage," <i>J. Mol. Biol.</i> , 1991, 222, 581-597	
	CE	Masui, H., et al., "Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes," <i>Cancer Res.</i> , November 1986, 46, 5592-5598	
	CF	Miller, A.D., et al., "Improved retroviral vectors for gene transfer and expression," <i>BioTechniques</i> , 1989, 7(9), 980-990	
	CG	Mir, L.M., et al., "Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle," <i>C.R. Acad. Sci. Paris</i> , 1998, 321, 893-899	
	CH	Morioka, N., et al., "A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients," <i>J. Immunol.</i> , 1994, 153, 5650-5658	
	CI	Morrison, S.L., et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> , November 1984, 81, 6851-6855	
	CJ	Neuberger, M.S., et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , December 1984, 312, 604-608	
<i>MB</i>	CK	Nielsen, P.E., et al., "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide," <i>Science</i> , December 6, 1991, 254, 1497-1500	
EXAMINER		DATE CONSIDERED 10/1/02	



Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
		Applicant <b>Jeffrey V. Ravetch</b>	
		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
M/B	CL	Noren, C.J., et al., "A general method for site-specific incorporation of unnatural amino acids in proteins," <i>Science</i> , April 14, <b>1989</b> , 244, 182-188	
	CM	Ono, M., et al., "Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB," <i>Nature</i> , September 19, <b>1996</b> , 383, 263-266	
	CN	Ono, M., et al., "Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling," <i>Cell</i> , July 25, <b>1997</b> , 90, 293-301	
	CO	Pegram, M.D., et al., "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 <sup>HER2/neu</sup> monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment," <i>J. Clin. Oncol.</i> , August <b>1998</b> , 16(8), 2659-2671	
↓	CP	Peoples, G.E., et al., "HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer," <i>J. Immunol.</i> , November 15, <b>1993</b> , 151(10), 5481-5491	
*	<del>CQ</del>	<del>Perbal, B., A Practical Guide to Molecular Cloning, Ausubel, F.M., et al. (Eds.), 1984</del>	
M/B	CR	Prati, E.G.P., et al., "Engineering of coordinated up- and down-regulation of two glycosyltransferases of the O-Glycosylation pathway in chinese hamster ovary (CHO) cells," <i>Biotechnol. and Bioeng.</i> , May 5, <b>2000</b> , 68(3), 239-244	
	CS	Presta,, L.G., "Antibody engineering," <i>Curr. Op. Struct. Biol.</i> , <b>1992</b> , 2, 593-596	
	CT	Ravetch, J.V., et al., "Fc receptors," <i>Annu. Rev. Immunol.</i> , <b>1991</b> , 9, 457-492	
↓ M/B	CU	Richardson, J.H., et al., "Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector," <i>Gene Ther.</i> , <b>1998</b> , 5, 635-644	
EXAMINER		DATE CONSIDERED 10/01/02	


\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.




Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
		Applicant <b>Jeffrey V. Ravetch</b>	
		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<i>MB</i>	CV	Riechmann, L., et al., "Reshaping human antibodies for therapy," <i>Nature</i> , March 1988, 332, 323-327	
<i>MB</i>	CW	Sahasrabudhe, D.M., et al., "Shared T cell-defined antigens on independently derived tumors," <i>J. Immunol.</i> , December 1, 1993, 151(11), 6302-6310	
*	CX	<del>Sambrook, et al., "Molecular Cloning: A Laboratory Manual," 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989</del>	
<i>MB</i>	CY	Samulski, R.J., et al., "A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication," <i>J. Virol.</i> , October 1987, 61(10), 3096-3101	
	CZ	Samulski, R.J., et al., "Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression," <i>J. Virol.</i> , September 1989, 63(9), 3822-3828	
	DA	Saudek, C.D., et al., "A preliminary trial of the programmable implantable medication system for insulin delivery," <i>N. Engl. J. Med.</i> , August 31, 1989, 321(9), 574-579	
	DB	Saviranta, P., et al., "Engineering the steroid-specificity of an anti-17 $\beta$ -estradiol fab by random mutagenesis and competitive phage panning," <i>Prot. Eng.</i> , 1998, 11(2), 143-152	
	DC	Sefton, M.V., "Implantable pumps," <i>CRC Crit. Rev. Biomed. Eng.</i> , England, 1987, 14(3), 201-240	
	DD	Shamamian, P., et al., "Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest," <i>Cancer Immunol. Immunother.</i> , 1994, 39, 73-83	
<i>MB</i>	DE	Shan, D., et al., "A poposis of malignant human B cells by ligation of CD20 with monoclonal antibodies," <i>Blood</i> , March 1, 1998, 91(5), 1644-1652	
EXAMINER <i>[Signature]</i>		DATE CONSIDERED <i>10/6/02</i>	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.





<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
		<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
*	<b>DF</b>	<del>Smolen, et al. (Eds.), "Controlled Drug Bioavailability, Drug Product Design and Performance," Wiley, NY, 1984</del>	
M/S	<b>DG</b>	Stratford-Perricaudet, L.D., et al., "Widespread long-term gene transfer to mouse skeletal muscles and heart," <i>J. Clin. Invest.</i> , August 1992, 90, 626-630	
	<b>DH</b>	Taji, H., et al., "Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody," <i>Jpn. J. Cancer Res.</i> , July 1998, 89, 748-756	
	<b>DI</b>	Takai, T., et al., "Augmented humoral and anaphylactic responses in FcγRII-deficient mice," <i>Nature</i> , January 25, 1996, 379, 346-349	
	<b>DJ</b>	Takai, T., et al., "Fcγ chain deletion results in pleiotrophic effector cell defects," <i>Cell</i> , February 11, 1994, 76, 519-529	
	<b>DK</b>	Takeda, S., et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <i>Nature</i> , April 4, 1985, 314, 452-454	
	<b>DL</b>	Treat, J., et al., "Liposome encapsulated doxorubicin preliminary results of phase 1 and phase II trials," in <i>Liposomes in the Therapy of Infectious Disease and Cancer</i> , 1989, 353-365	
	<b>DM</b>	Tutt, A.L., et al., "Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors," <i>J. Immunol.</i> , 1998, 161, 3176-3185	
	<b>DN</b>	Ulmer, J.B., et al., "Heterologous protection against influenza by injection of DNA encoding a viral protein," <i>Science</i> , March 19, 1993, 259, 1745-1749	
N	<b>DO</b>	Waldmann, T.A., "Lymphokine receptors: a target for immunotherapy of lymphomas," <i>Ann. Oncol.</i> , 1994, 5 Supp. 1, S13-S17	
<b>EXAMINER</b> 		<b>DATE CONSIDERED</b> 10/02/02	

\* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
		Applicant <b>Jeffrey V. Ravetch</b>	
		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
MB	<b>DP</b>	Ward, E.S., et al., "The effector functions of immunoglobulins: implications for therapy," <i>Therapeutic Immunol.</i> , <b>1995</b> , 2, 77-94	
	<b>DQ</b>	Ward, E.S., et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , October 12, <b>1989</b> , 341, 544-546	
	<b>DR</b>	Williams, R.S., et al., "Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles," <i>Proc. Natl. Acad. Sci. USA</i> , April <b>1991</b> , 88, 2726-2730	
	<b>DS</b>	Wilson, J.M., "Hepatocyte-directed gene transfer <i>in vivo</i> leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits," <i>J. Biol. Chem.</i> , January 15, <b>1992</b> , 267(2), 963-967	
	<b>DT</b>	Wu, G.Y., et al., "Receptor-mediated <i>in vitro</i> gene transformation by a soluble DNA carriers system," <i>J. Biol. Chem.</i> , April 5, <b>1987</b> , 262(10), 4429-4432	
	<b>DU</b>	Wu, G.Y., et al., "Receptor-mediated gene delivery and expression <i>in vivo</i> ," <i>J. Biol. Chem.</i> , October 15, <b>1988</b> , 263(29), 14621-14624	
	<b>DV</b>	Yang, C., et al., "Antisense suppression of proline-directed protein kinase F <sub>A</sub> enhances chemosensitivity in human prostate," <i>Clin. Cancer Res.</i> , March <b>2000</b> , 6, 1024-1030	
	<b>DW</b>	Yang, L., et al., "Expression of <i>ERCC1</i> antisense rna abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair," <i>Clin. Cancer Res.</i> , March <b>2000</b> , 6, 773-781	
	<b>DX</b>	Yuan, R., et al., "Antibody-mediated modulation of <i>cryptococcus neoformans</i> infection is dependent on distinct Fc receptor functions and IgG subclasses," <i>J. Exp. Med.</i> , February 16, <b>1998</b> , 187(4), 641-648	
	<b>DY</b>	Lin, S., et al., "Giving inhibitory receptors," <i>Science</i> , January 19, <b>2001</b> , 291, 445-446	
MB	<b>DZ</b>	Samuelsson, A., et al., "Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor," <i>Science</i> , January 19, <b>2001</b> , 291, 484-486	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 10/01/02	



<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
		<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
M/B	EA	Allan, R., et al. "Studies on the complement-binding site of rabbit immunoglobulin G-I. Modification of tryptophan residues and their role in anticomplementary activity of rabbit IgG" <i>Immunochemistry</i> , 1974, 11(4), 175-180	
	EB	Angal, S., et al., "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody" <i>Molecular Immunology</i> , 1993, 30(1), 105-108	
	EC	Armour, K.L., et al., "Recombinant human IgG molecules lacking Fc\147 receptor I binding and monocyte triggering activities" <i>European Journal of Immunology</i> , 1999, 29(8), 2613-2624	
	ED	Bloom, J.W., et al., "Intrachain disulfide bond in the core hinge region of human IgG4" <i>Protein Science</i> , 1997, 6, 407-415	
	EE	Bredius, R.G.M., et al., "Role of neutrophil Fc\147norRIIa (CD32) and Fc\147norRIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes" <i>Immunology</i> , 1994, 83(4), 624-630	
	EF	Brekke, O.H., et al., "Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis" <i>European Journal of Immunology</i> , 1994, 24(10), 2542-2547	
	EG	Burmeister, W.P., et al., "Crystal structure of the complex of rat neonatal Fc receptor with Fc" <i>Nature</i> , 1994, 372(6504), 379-383	
	EH	Burton, D.R., et al., "Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI)" <i>Molecular Immunology</i> , 1988, 25(11), 1175-1181	
	EI	Burton, D.R., et al., "The Clq receptor site on immunoglobulin G" <i>Nature</i> , 1980, 288(5789), 338-344	
↓ M/B	EJ	Burton, D.R., "Human antibody effector function," <i>Advances in Immunol.</i> , 1992, 51, 1-84	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
		Applicant <b>Jeffrey V. Ravetch</b>	
		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
MVB	EK	Canfield, S.M., et al., "The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the C <sub>H</sub> 2 domain and is modulated by the hinge region" <i>Journal of Experimental Medicine</i> , <b>1991</b> , 173(6), 1483-1491	
	EL	Capon, D.J., et al., "Designing CD4 Immunoadhesins for AIDS Therapy" <i>Nature</i> , <b>1989</b> , 337, 525-531	
	EM	Chappel, M.S., et al., "Identification of Secondary FcγRI Binding Site within a Genetically Engineered Human IgG Antibody" <i>Journal of Biological Chemistry</i> , <b>1993</b> , 268, 25124-25131	
	EN	Chappel, M.S., et al., "Identification of the Fcγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies" <i>Proc. Natl. Acad. Sci. USA</i> , <b>1991</b> , 88(20), 9036-9040	
	EO	Clynes, R., et al., "Cytotoxic antibodies trigger inflammation through Fc receptors" <i>Immunity</i> , <b>1995</b> , 3(1), 21-26	
	EP	Clynes, R., et al., "Fc receptors are required in passive and active immunity to melanoma" <i>Proc. Natl. Acad. Sci. USA</i> , <b>1998</b> , 95(2), 652-656	
	EQ	Clynes, R., et al., "Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors" <i>Journal of Experimental Medicine</i> , <b>1999</b> , 189(1), 179-185	
	ER	Clynes, R., et al., "Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis" <i>Science</i> , <b>1998</b> , 279(5353), 1052-1054	
ES	Cosimi, A.B., "Clinical Development of ORTHOCLONE OKT3" <i>Transplantation Proceedings</i> , <b>1987</b> , (Suppl 1) XIX(2), 7-16		
MVB	ET	Duncan, A.R., et al., "Localization of the binding site for the human high-affinity FC receptor on IgG" <i>Nature</i> , <b>1988</b> , 332, 563-564	
EXAMINER		DATE CONSIDERED 10/01/02	





<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
		Applicant <b>Jeffrey V. Ravetch</b>	
		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>MB</b>	<b>EU</b>	Duncan, A.R., et al., "The binding site for Clq on IgG" <i>Nature</i> , <b>1988</b> , 332, 738-740	
	<b>EV</b>	Gazzano-Santoro, H., et al., "A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody" <i>Journal of Immunological Methods</i> , <b>1997</b> , 202, 163-171	
	<b>EW</b>	Gergely, J., et al., "Fc receptors on lymphocytes and K cells" <i>Biochemical Society Transactions</i> , <b>1984</b> , 12(5), 739-743	
	<b>EX</b>	Ghebrehiwet, B., et al., "Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q" <i>Journal of Experimental Medicine</i> , <b>1994</b> , 179(6), 1809-1821	
	<b>EY</b>	Ghetie, V., et al., "FcRn: the MHC class I-related receptor that is more than an IgG transporter" <i>Immunology Today</i> , <b>1997</b> , 18(12), 592-598	
	<b>EZ</b>	Ghetie, V., et al., "Abnormally short serum half-lives of IgG in/1422-microglobulin-deficient mice" <i>European Journal of Immunology</i> , <b>1996</b> , 26(3), 690-696	
	<b>FA</b>	Ghetie, V., et al., "Increasing the serum persistence of an IgG fragment by random mutagenesis" <i>Nature Biotechnology</i> , <b>1997</b> , 15(7), 637-640	
	<b>FB</b>	Gorman, C.M., et al., "Transient Production of Proteins Using an Adenovirus Transformed Cell Line" <i>DNA Prot. Eng. Tech.</i> , <b>1990</b> , 2(1), 3-10	
	<b>FC</b>	Graham, F.L., et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <i>J. Gen. Virol.</i> , <b>1977</b> , 36, 59-74	
	<b>FD</b>	Greenwood, J., et al., "Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis" <i>Therapeutic Immunology</i> , <b>1994</b> , 1(5), 247-255	
	<b>FE</b>	Greenwood, J., et al., "Structural motifs involved in human IgG antibody effector functions" <i>European Journal of Immunology</i> , <b>1993</b> , 23(5), 1098-1104.	
<b>✓</b> <b>MB</b>	<b>FF</b>	Guddat, L.W., et al., "Three-dimensional structure of a human immunoglobulin with a hinge deletion" <i>PNAS (USA)</i> , <b>1993</b> , 90, 4271-4275	
<b>EXAMINER</b> <i>[Signature]</i>		<b>DATE CONSIDERED</b> <i>10/1/02</i>	



<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
		<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
MB	FG	Haagen, I., et al., "Interaction of Human Monocyte Fc $\gamma$ 147 Receptors with Rat IgG2b: A New Indicator for the Fc $\gamma$ 147RIIa (R-H131) Polymorphism" <i>J. Immunol.</i> , <b>1995</b> , 154, 1852-1860	
	FH	Hadley, A.G., et al., "The functional activity of Fc $\gamma$ 147RII and Fc $\gamma$ 147RIII on subsets of human lymphocytes" <i>Immunology</i> , <b>1992</b> , 76(3), 446-451	
	FI	Harris, L.J., et al., "Crystallographic Structure of an Intact IgG1 Monoclonal Antibody" <i>Journal of Molecular Biology</i> , <b>1998</b> , 275, 861-872	
	FJ	Harris, L.J., et al., "Refined Structure of an Intact IgG2a Monoclonal Antibody" <i>Biochemistry</i> , <b>1997</b> , 36, 1581-1597	
	FK	Hatta, Y., et al., "Association of Fc $\gamma$ 147 receptor IIIB, but not of Fc $\gamma$ 147 receptor IIA and IIIA, polymorphisms with systemic lupus erythematosus in Japanese" <i>Genes and Immunity</i> , <b>1999</b> , 1, 53-60	
	FL	Heiken, H., et al., "T lymphocyte development in the absence of Fc $\gamma$ 145 receptor $\gamma$ 147 subunit: analysis of thymic-dependent and independent $\gamma$ 141 $\gamma$ 142 and $\gamma$ 147 $\gamma$ 144 pathways" <i>European Journal of Immunology</i> , <b>1996</b> , 26(8), 1935-1943	
	FM	Henry, A.J., et al., "Participation of the N-terminal region of C $\gamma$ 1453 in the binding of human IgE to its high-affinity receptor F $\gamma$ 145RI" <i>Biochemistry</i> , <b>1997</b> , 36, 15568-15578	
	FN	Hogarth, P.M., et al., "Characterization of FcR Ig-binding sites and epitope mapping" <i>Immunomethods</i> , <b>1994</b> , 4(1), 17-24	
	FO	Huizinga, T.W.J., et al., "Binding Characteristics of Dimeric IgG Subclass Complexes to Human Neutrophils" <i>Journal of Immunology</i> , <b>1989</b> , 142, 2359-2364	
MB	FP	Hulett, M.D., et al., "Chimeric Fc Receptors Identify Functional Domains of the Murine High Affinity Receptors for IgG" <i>J. Immunol.</i> , <b>1991</b> , 147, 1863-1868	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 10/01/02	




<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
		<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>MB</b>	<b>FQ</b>	Jaakkola, K., et al., "In vivo detection of vascular adhesion protein-1 in experimental inflammation" <i>American Journal of Pathology</i> , <b>2000</b> , 157(2), 463-471	
	<b>FR</b>	Janeway et al. Immunobiology, The Immune System in Health and Disease, <i>CB Ltd and Garland Publishing Inc., NY &amp; London</i> , <b>1994</b> , 4 pages	
	<b>FS</b>	Jefferis, R., et al., "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFc\147R)" <i>Molecular Immunology</i> , <b>1990</b> , 27(12), 1237-1240	
	<b>FT</b>	Kabat, E. et al. Sequences of Proteins of Immunological Interest, <i>5th edition, Bethesda, MD:NIH</i> , <b>1991</b> , Vol. 1, 669, 671, 687, 696	
	<b>FU</b>	Kim, J.K., et al., "Catabolism of the Murine IgG1 Molecule: Evidence That Both CH2-CH3 Domain Interfaces are Required for Persistence of IgG1 in the Circulation of Mice" <i>Scandinavian Journal Of Immunology</i> , <b>1994</b> , 40(4), 457-465	
	<b>FV</b>	Kim, J.K., et al., "Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis" <i>European Journal of Immunology</i> , <b>1994</b> , 24, 542-548	
	<b>FW</b>	Kim, J.K., et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo" <i>Nature</i> , <b>1993</b> , 362, 841-844	
	<b>FX</b>	Kim, J.K., et al., "Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor" <i>European Journal of Immunology</i> , <b>1994</b> , 24, 2429-2434	
	<b>FY</b>	Kim, K.J., et al., "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies" <i>Growth Factors</i> , <b>1992</b> , 7(1), 53-64	
<b>N N/S</b>	<b>FZ</b>	Koene, H.R., et al., "FcγRIIIa-158V/F Polymorphism Influences the Binding of the IgG by Natural Killer Cell Fc\147RIIIa, Independently of the Fc\147RIIIa-48L/R/H Phenotype" <i>Blood</i> , <b>1997</b> , 90(3), 1109-1114	
<b>EXAMINER</b> 		<b>DATE CONSIDERED</b> 10/6/02	



<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
		<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
MP	GA	Kunkel, T.A., "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection" <i>Proc. Natl. Acad. Sci.</i> , <b>1985</b> , 82, 488-492	
	GB	Lauvrak, V., et al., "Identification and characterisation of C1q-binding phage displayed peptides" <i>Biological Chemistry</i> , <b>1997</b> , 378(12), 1509-1519	
	GC	Lehrnbecher, T., et al., "Variant genotypes of Fc $\gamma$ RIIIA influence the development of Kaposi's sarcoma in HIV-infected men" <i>Blood</i> , <b>2000</b> , 95(7), 2386-2390	
	GD	Lehrnbecher, T., et al., "Variant genotypes of the low-affinity Fc $\gamma$ receptors in two control populations and a review of low-affinity Fc $\gamma$ receptor polymorphisms in control and disease populations" <i>Blood</i> , <b>1999</b> , 94(12), 4220-4232	
	GE	Li, M., et al., "Reconstitution of human Fc $\gamma$ RIII cell type specificity in transgenic mice" <i>Journal of Experimental Medicine</i> , <b>1996</b> , 183(3), 1259-1263	
	GF	Lifely, M.R., et al., "Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions" <i>Glycobiology</i> , <b>1995</b> , 5(8), 813-822	
	GG	Lorenz, A., "Strong association between the responder status of the Fc $\gamma$ II receptor and recurrent spontaneous abortion," <i>Europ. J. Immunogenetics</i> , <b>1995</b> , 22, 397-401	
	GH	Lucas, B.K., et al., "High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector" <i>Nucleic Acids Research</i> , <b>1996</b> , 24(9), 1774-1779	
	GI	Lund, J., et al., "Human Fc $\gamma$ RI and Fc $\gamma$ RII interact with distinct but overlapping sites on human IgG" <i>Journal of Immunology</i> , <b>1991</b> , 147(8), 2657-2662	
MP ↓ MB	GJ	Lund, J., et al., "Multiple binding sites on the C $\gamma$ 2 domain of IgG for mouse Fc $\gamma$ RII" <i>Molecular Immunology</i> , <b>1992</b> , 29(1), 53-59	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 10/01/02	





<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
		<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
MB	<b>GK</b>	Lund, J. et al., "Multiple Interactions of the IgG with Its Core Oligosaccharide Can Modulate Recognition by Complement and Human Fc $\gamma$ 147 Receptor I and Influence the Synthesis of Its Oligosaccharide Chains" <i>J. Immunol.</i> , <b>1996</b> , <i>157</i> , 4963-4969	
	<b>GL</b>	Lund, J., et al., "Oligosaccharide-protein interactions in IgG can modulate recognition by Fc $\gamma$ 147 receptors" <i>FASEB Journal</i> , <b>1995</b> , <i>9</i> , 115-119	
	<b>GM</b>	Medesan, C., et al., "Comparative studies of rat IgG to further delineate the Fc:Fc $\gamma$ RN interaction site" <i>European Journal of Immunology</i> , <b>1998</b> , <i>28</i> , 2092-2100	
	<b>GN</b>	Medesan, C., et al., "Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1" <i>Journal of Immunology</i> , <b>1997</b> , <i>158</i> (5), 2211-2217	
	<b>GO</b>	Medesan, C., et al., "Localization of the site of the IgG molecule that regulates maternofetal transmission in mice" <i>European Journal of Immunology</i> , <b>1996</b> , <i>26</i> (10), 2533-2536	
	<b>GP</b>	Meng, Y.G., et al., "Green fluorescent protein as a second selectable marker for selection of high producing clones from transfected CHO cells" <i>Gene</i> , <b>2000</b> , <i>242</i> , 201-207	
	<b>GQ</b>	Miller, K.L., et al., "A Novel Role for the Fc Receptor $\gamma$ 147 Subunit: Enhancement of the Fc $\gamma$ 147R Ligand Affinity" <i>Journal of Experimental Medicine</i> , <b>1996</b> , <i>183</i> , 2227-2233	
	<b>GR</b>	Morgan, A., et al., "The N-terminal end of the C $\gamma$ 2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc $\gamma$ 147RI and Fc $\gamma$ 147RIII binding" <i>Immunology</i> , <b>1995</b> , <i>86</i> (2), 319-324	
	<b>GS</b>	Morrison, S.L. et al., "Structural Determinants of Human IgG Function" <i>Immunologist</i> , <b>1994</b> , <i>2</i> , 119-124	
MB	<b>GT</b>	Nagarajan, S., et al., "Ligand binding and phagocytosis by CD16 (Fc $\gamma$ 147 receptor III) isoforms. Phagocytic signaling by associated $\gamma$ 172 and $\gamma$ 147 subunits in Chinese hamster ovary cells" <i>Journal of Biological Chemistry</i> , <b>1995</b> , <i>270</i> (43), 25762-25770	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 10/01/02	



<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
		<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
MB	GU	Ngo, J.T., et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox" <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz & Le Grand, Boston: Birkhauser, 1994, 491-495	
	GV	Nieto, A., et al., "Involvement of the Fc $\gamma$ 147 receptor IIIA genotypes in susceptibility to rheumatoid arthritis" <i>Arthritis and Rheumatism</i> , 2000, 43(4), 735-739	
	GW	Okada, H., et al., "Cutting Edge: Role of the inositol phosphatase SHIP in B cell receptor-induced Ca <sup>2+</sup> nor oscillatory response" <i>Journal of Immunology</i> , 1998, 161(10), 5129-5132	
	GX	Papac, D.I., et al., "A high-throughput microscale method to release N-linked oligosaccharide from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis" <i>Glycobiology</i> , 1998, 8(5), 445-454	
	GY	Papac, D.I., et al., "Analysis of Acidic Oligosaccharides and Glycopeptides by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry" <i>Anal. Chem.</i> , 1996, 68, 3215-3223	
	GZ	Popov, S., et al., "The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn" <i>Molecular Immunology</i> , 1996 33(6), 521-530	
	HA	Porges, A.J., et al., "Novel Fc $\gamma$ 147 Receptor I Family Gene Products in Human Mononuclear Cells" <i>J. Clin. Invest.</i> , 1992, 90, 2102-2109	
	HB	Presta, L.G., et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" <i>Cancer Research</i> , 1997, 57(20), 4593-4599	
	HC	Raghavan, M., et al., "Fc Receptors and their Interactions with Immunoglobulins" <i>Annu. Rev. Cell. Dev. Biol.</i> , 1996, 12, 181-220	
✓ MB	HD	Raghavan, M., et al., "Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants" <i>Biochemistry</i> , 1995, 34(45), 14649-14657	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 10/01/02	



Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
		Applicant <b>Jeffrey V. Ravetch</b>	
		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>MB</b>	<b>HE</b>	Ravetch, J.V., et al., "Divergent roles for Fc receptors and complement in vivo" <i>Annual Review of Immunology</i> , <b>1998</b> , <i>16</i> , 421-432	
	<b>HF</b>	Ravetch, J.V., "Fc receptors" <i>Current Opinion in Immunology</i> , <b>1997</b> , <i>9(1)</i> :121-125	
	<b>HG</b>	Ravetch, J.V., "Fc receptors: rubor redux" <i>Cell</i> , <b>1994</b> , <i>78(4)</i> , 553-560	
	<b>HH</b>	Reff, M.E., et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20" <i>Blood</i> , <b>1994</b> , <i>83(2)</i> , 435-445	
	<b>HI</b>	Sarmay, G., et al., "Ligand inhibition studies on the role of Fc receptors in antibody-dependent cell-mediated cytotoxicity" <i>Molecular Immunology</i> , <b>1984</b> , <i>21(1)</i> , 43-51	
	<b>HJ</b>	Sarmay, G., et al., "Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc\147\nor receptor" <i>Molecular Immunology</i> , <b>1992</b> , <i>29(5)</i> , 633-639	
	<b>HK</b>	Sensel, M.G., et al., "Amino acid differences in the N-terminus of C\subH\nor2 influence the relative abilities of IgG2 and IgG3 to activate complement" <i>Molecular Immunology</i> , <b>1997</b> , <i>34(14)</i> , 1019-1029	
	<b>HL</b>	Shores, E.W., et al., "T cell development in mice lacking all T cell receptor \172 family members (\172, \150, and Fc\145RI\147)" <i>Journal of Experimental Medicine</i> , <b>1998</b> , <i>187(7)</i> , 1093-1101	
	<b>HM</b>	Sondermann, P., et al., "Crystal structure of the soluble form of the human Fc\147-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution" <i>EMBO Journal</i> , <b>1999</b> , <i>18(5)</i> , 1095-1103	
<b>MB</b>	<b>HN</b>	Sondermann, P., et al., "The 32-A crystal structure of the human IgG1 Fc Fragment-Fc\147RIII complex" <i>Nature</i> , <b>2000</b> , <i>406</i> , 267-273	
EXAMINER		DATE CONSIDERED <i>10/01/02</i>	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
		Applicant <b>Jeffrey V. Ravetch</b>	
		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
MB	<b>HO</b>	Strohmeier, G., et al., "Neutrophil functional responses depend on immune complex valency" <i>Journal of Leukocyte Biology</i> , <b>1995</b> , 58(4), 403-414	
	<b>HP</b>	Strohmeier, G.R., et al., "Role of the Fc $\gamma$ 147\norR subclasses Fc $\gamma$ 147\norRII and Fc $\gamma$ 147\norRIII in the activation of human neutrophils by low and high valency immune complexes" <i>Journal of Leukocyte Biology</i> , <b>1995</b> , 58(4), 415-422	
	<b>HQ</b>	Suzuki, Y., et al., "Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis" <i>Kidney International</i> , <b>1998</b> , 54(4), 1166-1174	
	<b>HR</b>	Sylvestre, D.L., et al., "A dominant role for mast cell Fc receptors in the Arthus reaction" <i>Immunity</i> , <b>1996</b> , 5(4), 387-390	
	<b>HS</b>	Sylvestre, D.L., , "Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade" <i>Science</i> , <b>1994</b> , 265(5175), 1095-1098	
	<b>HT</b>	Sylvestre, D., et al., "Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice" <i>Journal of Experimental Medicine</i> , <b>1996</b> , 184(6), 2385-2392	
	<b>HU</b>	Tamm, A., et al., "The IgG binding site of human Fc $\gamma$ 147\norRIIIB receptor involves CC' and FG loops of the membrane-proximal domain" <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271(7), 3659-3666	
	<b>HV</b>	Tao, M., et al., "Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation" <i>Journal of Experimental Medicine</i> , <b>1993</b> , 178(2), 661-667	
	<b>HW</b>	Tao, M., et al., "Studies of aglycosylated chimeric mouse-human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region" <i>Journal of Immunology</i> , <b>1989</b> , 143(8), 2595-2601	
MB	<b>HX</b>	Tao, M., et al., "The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the C $\gamma$ 2 domain" <i>Journal of Experimental Medicine</i> , <b>1991</b> , 173(4), 1025-1028	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 10/6/02	



<b>Form PTO-1449 Modified</b>		<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
		<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
MPB	<b>HY</b>	Tax, W.J.M., et al., "Fc receptors for mouse IgG1 on human monocytes: polymorphism and role in antibody-induced T cell proliferation," <i>Journal of Immunology</i> , <b>1984</b> , 133(3), 1185-1189	
	<b>HZ</b>	Ting, A.T., et al., "Fc\147 receptor activation induces the tyrosine phosphorylation of both phospholipase C (PLC)-\1471 and PLC-\1472 in natural killer cells" <i>Journal of Experimental Medicine</i> <b>1992</b> , 176(6), 1751-1755	
	<b>IA</b>	Umana, P., et al., "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity" <i>Nature Biotechnology</i> , <b>1999</b> , 17, 176-180	
	<b>IB</b>	Urfer, R., et al., "High resolution mapping of the binding site of TrkA for nerve growth factor and TrkC for neurotrophin-3 on the second immunoglobulin-like domain of the Trk receptors" <i>Journal of Biological Chemistry</i> , <b>1998</b> , 273(10), 5829-5840	
	<b>IC</b>	Van de Winkel, J.G.J., et al., "Biology of human immunoglobulin G Fc receptors" <i>Journal of Leukocyte Biology</i> , <b>1991</b> , 49(5), 511-524	
	<b>ID</b>	Vance, B.A., et al., "Binding of monomeric human IgG defines an expression polymorphism of Fc\147RIII on large granular lymphocyte/natural killer cells" <i>Journal of Immunology</i> , <b>1993</b> , 151(11), 6429-6439	
	<b>IE</b>	Warmerdam, P.A.M., et al., "A single amino acid in the second Ig-like domain of the human Fc\147nor receptor II is critical for human IgG2 binding" <i>Journal of Immunology</i> , <b>1991</b> , 147(4), 1338-1343	
	<b>IF</b>	Weng, Z., et al., "Computational determination of the structure of rat Fc bound to the neonatal Fc receptor" <i>Journal of Molecular Biology</i> , <b>1998</b> , 282(2), 217-225	
MPB	<b>IG</b>	Werther, W.A., et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" <i>J. of Immunology</i> , <b>1996</b> , 157, 4986-4995	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b> 10/01/02	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
		Applicant <b>Jeffrey V. Ravetch</b>	
		Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>MP</b>	<b>IH</b>	Woof, J.M., et al., "Localisation of the monocyte-binding region on human immunoglobulin G" <i>Molecular Immunology</i> , <b>1986</b> , 23(3), 319-330	
	<b>II</b>	Wright, A., et al., "Effect of altered C <sub>H</sub> 2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1" <i>Journal of Experimental Medicine</i> , <b>1994</b> , 180(3), 1087-1096	
	<b>IJ</b>	Wu, J., et al., "A novel polymorphism of Fc $\gamma$ RIIIa (CD16) alters receptor function and predisposes to autoimmune disease" <i>Journal of Clinical Investigation</i> , <b>1997</b> , 100(5), 1059-1070	
	<b>IK</b>	Xu, Y., et al., "The N-terminal sequence of the C <sub>H</sub> 2 domain controls the differential ability of human IgG1 and IgG2 to activate complement" <i>Journal of Immunology</i> , <b>1993</b> , (abstract no. 862), 150(8), 152A	
<b>MP</b>	<b>IL</b>	Yap S., et al., "Human Fc gamma receptor IIA (Fc $\gamma$ RIIA) genotyping and association with systemic lupus erythematosus (SLE) in Chinese and Malays in Malaysia" <i>Lupus</i> , <b>1999</b> , 8(4), 305-310	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	


10/01/02



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>TRU-0005</b>	Serial No. <b>09/834,321</b>
	Applicant <b>Jeffrey V. Ravetch</b>	
	Filing Date <b>April 13, 2001</b>	Group <b>Not Yet Assigned</b>

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
MB	IM	4,816,567	03/28/89	Cabilly, et al.	530	387
	IN	4,946,778	08/07/90	Ladner, et al.	435	69.6
	IO	5,034,506	07/23/91	Summerton, et al.	528	391
	IP	5,132,405	07/21/92	Huston, et al.	530	387.3
	IQ	5,459,127	10/17/95	Felgner, et al.	514	7
	IR	5,476,786	12/19/95	Huston	435	252.33
	IS	5,554,601	09/10/96	Simpkins, et al.	514	182
	IT	5,580,859	12/03/96	Felgner, et al.	514	44
	IU	5,589,466	12/31/96	Felgner, et al.	514	44
	IV	5,624,821	04/29/97	Winter, et al.	435	69.6
	IW	5,637,684	06/10/97	Cook, et al.	536	23.1
	IX	5,677,437	10/14/77	Teng, et al.	536	23.1
	IY	5,773,231	06/30/98	Medford, et al.	435	7.24
	IZ	5,780,607	07/14/98	Goodnow, Jr., et al.	536	22.1
	JA	5,783,682	07/21/98	Cook, et al.	536	24.3
	JB	5,792,844	08/11/98	Sanghvi, et al.	536	23.1
	JC	5,811,234	09/22/98	Roninson, et al.	435	6
	JD	5,814,500	09/29/98	Dietz	435	172.3
	JE	5,834,597	11/10/98	Tso, et al.	530	387.3
MB	JF	5,981,229	11/09/99	Masure, et al.	435	69.3
EXAMINER <i>[Signature]</i>				DATE CONSIDERED <i>10/01/02</i>		



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>
	<b>Applicant</b> <b>Jeffrey V. Ravetch</b>	
	<b>Filing Date</b> <b>April 13, 2001</b>	<b>Group</b> <b>Not Yet Assigned</b>

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
MB	JG	5,648,260	07/15/97	Winter, et al.	435	252.3
	JH	4,752,601	06/21/88	Hahn	514	14
	JI	5,348,876	09/20/94	Michaelsen, et al.	435	240.2
	JJ	5,624,821	04/29/97	Winter, et al.	435	69.6
	JK	5,648,260	07/15/97	Winter, et al.	435	252.3
	JL	5,698,449	12/16/97	Baumann, et al.	436	507
	JM	5,736,137	04/07/98	Anderson, et al.	424	133.1
	JN	5,985,599	11/16/99	McKenzie, et al.	435	69.1
	JO	US 6,194,551 B1	02/27/01	Idusogie, et al.	530	387.1
	JP	09/483,588	01/14/00	Presta		
MB	JQ	09/713,425	11/15/00	Presta		

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
MB	JR	2,012,311	09/16/90	Canada		
	JS	WO 86/01533	03/13/86	PCT		
	JT	WO 88/07089	09/22/88	PCT		
	JU	WO 89/07142	08/10/89	PCT		
	JV	WO 92/05263	04/02/92	PCT		
	JW	WO 94/21807	09/29/94	PCT		
	JX	WO 95/05468	02/23/95	PCT		
MB	JY	WO 95/18863	07/13/95	PCT	X abstract	

EXAMINER

DATE CONSIDERED 10/05/02





<b>Form PTO-1449 Modified</b>				<b>Docket No.</b> <b>TRU-0005</b>	<b>Serial No.</b> <b>09/834,321</b>	
<b>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>				<b>Applicant</b> <b>Jeffrey V. Ravetch</b>		
				<b>Filing Date</b> <b>April 13, 2001</b>		<b>Group</b> <b>Not Yet Assigned</b>
<b>FOREIGN PATENT DOCUMENTS</b>						
<b>Examiner Initial</b>		<b>Document No.</b>	<b>Date</b>	<b>Country</b>	<b>Translation</b> <b>YES NO</b>	
<i>MB</i>	<i>JZ</i>	WO 95/21931	08/17/95	PCT	X abstract	
	<i>KA</i>	WO 95/28494	10/26/95	PCT		
	<i>KB</i>	WO 96/17823	06/13/96	PCT	X abstract	
	<i>KC</i>	WO 96/25508	08/22/96	PCT	X abstract	
	<i>KD</i>	WO 98/05787	02/12/98	PCT		
	<i>KE</i>	WO 98/23289	06/04/98	PCT		
	<i>KF</i>	WO 99/01157	01/14/99	PCT	X abstract	
	<i>KG</i>	WO 99/01158	01/14/99	PCT	X abstract	
	<i>KH</i>	WO 99/01175	01/14/99	PCT		
	<i>KI</i>	WO 99/51642	10/14/99	PCT		
	<i>KJ</i>	WO 00/09560	02/24/00	PCT		
	<i>KK</i>	WO 88/07089	09/22/88	PCT		
	<i>KL</i>	WO 94/29351	12/22/94	PCT		
	<i>KM</i>	WO 97/28267	08/07/97	PCT		
	<i>KN</i>	WO 97/44362	11/27/97	PCT		
	<i>KO</i>	WO 98/23289	06/04/98	PCT		
	<i>KP</i>	WO 98/52975	11/26/98	PCT	X abstract	
	<i>KQ</i>	WO 99/43713	09/02/99	PCT		
<i>MB</i>	<i>KR</i>	WO 99/58572	11/18/99	PCT		
<b>EXAMINER</b> <i>[Signature]</i>				<b>DATE CONSIDERED</b> <i>10/2/02</i>		